

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 November 2001 (15.11.2001)

PCT

(10) International Publication Number
WO 01/85191 A1

(51) International Patent Classification⁷: **A61K 35/84,**
A61P 37/08, 29/00

(21) International Application Number: PCT/JP01/02236

(22) International Filing Date: 21 March 2001 (21.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2000-136283 9 May 2000 (09.05.2000) JP

(71) Applicant (for all designated States except US):
TSUKUBA BIOSYSTEM, LTD. [JP/JP]; 802-36,
Edosaki Otsu, Edosaki-machi, Inashiki-gun, Ibaraki
305-0509 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MAEKAWA,**
Takaaki [JP/JP]; 802-36, Edosaki Otsu, Edosaki-machi,
Inashiki-gun, Ibaraki 305-0509 (JP). **ISODA, Hiroko**
[JP/JP]; 811-1, Azuma 1-chome, Tsukuba-shi, Ibaraki
305-0031 (JP).

(74) Agents: **AGATA, Akira** et al.; Agata Patent Office,
3rd Floor, Ikeden Building, 12-5, Shimbashi 2-chome,
Minato-ku, Tokyo 105-0004 (JP).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **HYALURONIDASE ACTIVITY AND ALLERGENIC CELL ACTIVITY INHIBITOR**

(57) Abstract: Disclosed is a novel hyaluronidase activity and allergenic cell activity inhibitive substance useful as an effective ingredient in an anti-inflammatory or antiallergic medicament, which is an ethyl alcohol extract from body tissues or mycelia tissues of a fungus *Agaricus blazei*. The desired inhibitive activity of the ethyl alcohol extract is significantly higher than the corresponding hot water extract of the same fungous tissues. This difference is very prominent when the *Agaricus blazei* fungus cultured in a culture medium containing wheat bran and pinewood chips in combination is used as the starting material of the ethyl alcohol extraction.

WO 01/85191 A1

DESCRIPTION

HYALURONIDASE ACTIVITY AND ALLERGENIC CELL ACTIVITY INHIBITOR

5 Technical Field

The present invention relates to a novel hyaluronidase activity and allergenic cell activity inhibitor and a method for the preparation thereof as well as medical applications thereof as an effective ingredient of anti-inflammatory and
10 antiallergic medicaments.

Background Art

It is a noticeable trend in recent years not only in Japan but also in many other countries throughout the world
15 that allergic diseases are increasing year by year with an estimated rate of 10% annual increase in the number of allergic patients. So to say, allergic diseases belong to a kind of civilization diseases and are considered to be caused by uptake of heterogeneous proteins as a consequence of the
20 changes in the dietary and in the housing conditions. In addition, the increase in the allergic patients in recent years is partly due to the manifestation of latent patients as is the case in relation to the pollinosis which has come to the public attention.

25 As is known, hyaluronic acid is a biopolymer compound playing a very important role in the processes of ontogeny and homeostasis of tissues as well as phlogogenic reactions and wound healing. On the other hand, hyaluronidase is an enzyme to promote hydrolysis of hyaluronic acid and contained
30 in large amounts in the connective tissues of mammals. It is established that hyaluronidase has an activity to cause inflammation in the human body so that inflammation could be alleviated by inhibiting the activity of hyaluronidase. This is the reason for the recent demand for development of an
35 effective hyaluronidase activity inhibitor as an effective ingredient of anti-inflammatories.

On the other hand, hyaluronic acid is known as a natural moisturizing factor (NMF) and formulated in various kinds of toiletry and cosmetic preparations such as milky lotions and creams so that a hyaluronidase activity inhibitor could have
5 an application also as an ingredient of toiletry and cosmetic preparations to prevent decomposition of hyaluronic acid.

It is also known that allergenic cells such as the basophilic leukocytes among the blood cells and mast cells in the tissues isolate enzymes such as β -hexosaminidase and
10 histamine by degranulation to induce instantaneous allergic reactions such as asthma, hay fever and atopic eczema. Accordingly, it would be a good assumption that allergic diseases could be alleviated by inhibiting degranulation of basophilic leukocytes so that an effective inhibitor against
15 the degranulation activity of basophilic leukocytes has an application as an antiallergic agent.

A basidiomycetous fungus called agaric and having a scientific name of *Agaricus blazei* is an edible fungus as a kind of health foods having certain medicinal activity and
20 widely employed from old. While a great variety of constituents are contained in the body of an agaric fungus of which, however, little information is available, it is reported that a water-soluble compound contained in the body of an agaric fungus is identified to be β -D-glucans, in
25 particular, β -(1,3)-D-glucan and β -(1,6)-D-glucan, and has an anti-cancer activity.

Disclosure of Invention

In view of the above described various situations, the
30 present invention has an object, on one hand, to provide a novel hyaluronidase activity and allergenic cell activity inhibitor and an efficient method for the preparation thereof as well as to propose, on the other hand, a novel application of the inhibitor as an effective ingredient in anti-
35 inflammatory and antiallergic medicaments..

After extensive investigations undertaken with an object to develop a novel material capable of inhibiting the hyaluronidase activity and allergenic cell activity, the inventors have arrived at a discovery that an ethyl alcohol
5 extract from tissues of bodies or mycelia of a basidio-
mycetous fungus or, in particular, an agaric fungus exhibits strong inhibition against the hyaluronidase activity and allergenic cell activity and that the extract can be used as
10 an effective ingredient in anti-inflammatory and antiallergic medicaments leading to completion of the present invention on the base of this discovery.

Thus, the present invention provides a hyaluronidase activity and allergenic cell activity inhibitor which is an ethyl alcohol extract from tissues of bodies or mycelia of
15 *Agaricus blazei* or, generally, a basidiomycetous fungus. The origin of the agaric fungus, of which the fungous body tissues or mycelia tissues are subjected to extraction with ethyl alcohol, is not particularly limitative including the fungous bodies grown in the wild, cultured fungous bodies and
20 cultured bodies of mycelia. The gathering seasons, growth ages, culturing conditions and culturing periods of the agaric fungus bodies are also not particularly limitative.

Best Mode for Carrying Out the Invention

25 Although the desired activity of the ethyl alcohol extract from agaric fungous bodies or mycelia is not uniform depending on the growing conditions such as the formulation of the culture medium, any fungous bodies grown by a variety of growing methods can be used as the base material in the
30 present invention. While a variety of species are included in the genus of *Agaricus*, those agaric fungi can be used either singly or as a combination of two kinds or more as the base material in the invention. It is of course that the desired activity of the ethyl alcohol extract can be
35 synergistically increased by using several kinds of different agaricous fungi each giving high activity in combination.

Combined use of a first agaric fungus giving high hyaluronidase activity inhibitive effect and a second agaric fungus giving high inhibitive effect against degranulation activity of basophilic leukocytes could lead to exhibition of the anti-inflammatory and antiallergic activity for a composite medicament.

According to the method of the invention, the hyaluronidase activity and allergenic cell activity inhibitor can be obtained as an ethyl alcohol extract from tissues of bodies or mycelia of an agaric fungus. The ethyl alcohol as the extractant of the fungous tissues is not particularly limited to absolute alcohol but can contain water and other impurities each in a limited amount provided that the impurities do not disturb extraction of the active matters from the fungous tissues. When the ethyl alcohol as the extractant contains water, the content of water therein should not exceed 40% by weight or, desirably, 20% by weight. The volume of the ethyl alcohol used in the extraction treatment is not particularly limitative but should be sufficient to completely dissolve out the water-insoluble active matters contained in the fungous tissues.

When culturing of the agaric fungus is conducted for obtaining the fungous bodies or mycelia, the culture medium is admixed with 0.2 to 3 g/liter of a milled flour of agricultural and forestry raw materials such as wheat bran, bagasse, pinewood chips, pine seeds, wheat, foxtail millet, rice, rice straws, wheat straws and the like either singly or as a combination of two kinds or more. The culturing is conducted as a tank culture process usually for 3 to 14 days.

The fungous bodies or mycelia as grown and separated from the liquid culture medium are thoroughly washed with water to remove the adhering liquid culture medium and foreign materials followed by chopping into pieces, an ultrasonic treatment and grinding by using a grinding machine such as homogenizers into a pulpy form. It is optional that

this grinding process is preceded by air-drying or freeze-drying so as to give a dry powder by grinding.

In the next place, the fungous bodies or mycelia tissues thus ground are admixed with an appropriate volume of ethyl alcohol and the mixture is agitated at a temperature up to the boiling point of ethyl alcohol to dissolve out the alcohol-soluble matter in the fungous bodies or mycelia tissues followed by separation of the extract solution from the insoluble matter. Preferably, this extraction treatment is repeated several times in order to completely extract the extractable matter.

The thus obtained ethyl alcohol extract solution contains the hyaluronidase activity and allergenic cell activity inhibitor. The extract can be used as such as the effective ingredient of an anti-inflammatory or antiallergic medicament, if necessary, after dilution or concentration. A powdery material can be obtained by subjecting the extract solution to spray drying or freeze-drying. The thus obtained dry powder exhibits strong hyaluronidase activity and allergenic cell activity inhibition.

Being a constituent in the tissues of bodies or mycelia an agaric fungus which is employed as a food from old, the ethyl alcohol extract prepared in the above-described manner has absolutely no safety problem against human body. Accordingly, the ethyl alcohol extract can be used as an additive to toiletry and cosmetic preparations, medicaments and foodstuff either alone or in combination with other additives. The adding amount of the agaric extract naturally depends on the specific purpose of its addition to exhibit the desired effect. As an additive to a toiletry or cosmetic preparation, for example, the adding amount thereof can be in the range from 2 to 20 ppm by weight calculated as solid. When used as an additive in an orally administrable medicament, the administration dose thereof is usually in the range from 0.2 to 2 mg/kg body weight per day calculated as solid, if necessary, in portions a day.

The medicaments to which the agaric extract is added can be in a variety of medicament forms depending on the object of administration and administrative route including tablets, capsules, injection fluids, instillation fluids, triturations, suppositories, granules, ointments, suspensions, emulsions and others.

Since the ethyl alcohol extract from tissues of bodies or mycelia of agaric fungus exhibits strong anti-inflammatory and antiallergic activity, a health food having anti-inflammatory or antiallergic activity can be prepared by adding the extract to a conventional food provided that the food is not inhibitive against the anti-inflammatory or antiallergic activity of the extract. Types of the foods and beverages suitable to this purpose include bakery foods such as breads, confectionaries such as candies, various kinds of precooked foods, seasonings and so on without particular limitations.

In the following, the present invention is described in more detail by way of examples.

Following is the base formulation of the culture media used in the culturing of the agaric fungus conducted in the Examples.

	Magnesium sulfate heptahydrate	0.5 g
	Iron(II) sulfate heptahydrate	0.01 g
25	Yeast extract	1.0 g
	Barley flour	1.0 g
	Sucrose	30 g
	Deionized water	1000 ml

Examples

Eight culturing runs A, B, C, D, E, F, G and H of *Agaricus blazei* were carried out at 28 to 29 °C each in a liquid culture medium of the above described base formulation with or without addition of an auxiliary additive or additives selected from wheat bran, bagasse, which served as the sources of nitrogen, phosphorus and potassium, and pinewood chips each in an amount of 1 g. The culture medium

was inoculated with 5 g of the fungous bodies calculated as wet. The auxiliary additives and the culturing time in these culturing runs were as shown in Table 1 below.

After the end of the culturing time as indicated, a 10 g portion of wet bodies of the fungus as grown was taken from the culture medium and thoroughly rinsed with water to remove the liquid culture medium adhering to the surface of the fungous bodies. Thereafter, the fungous bodies were mashed by 5 cycles of ultrasonic treatments at 10 second intervals at 20 °C with a 100 watt output and 50 kHz ultrasonic frequency. The fungous body mash was admixed with four times by weight of absolute ethyl alcohol and thoroughly agitated therein at room temperature. The thus obtained dispersion of the fungous body mash was subjected to centrifugal separation at 1500 rpm for 2 minutes to collect the supernatant as an ethyl alcohol extract.

The ethyl alcohol extract solution was subjected to spray drying to give about 100 mg of an extract powder. For comparison, the same extraction procedure as above was undertaken for the fungous bodies obtained in the culturing runs A to H excepting for the replacement of four times by weight of ethyl alcohol as the extractant with four times by volume of hot water to give a hot water extract after 15 minutes of boiling of the aqueous dispersion of the fungous body mash.

The above obtained ethyl alcohol extract solutions and hot water extract solutions were each subjected to the evaluation tests of the hyaluronidase activity inhibition and allergenic cell activity inhibition in the following assay procedures 1 and 2, respectively.

Assay 1

A 0.025 ml portion of a solution prepared by dissolving 2.83 mg of bovine testis-origin hyaluronidase (a product by Sigma Co.) in 1 ml of a 0.1M acetate buffer solution of pH 4.0 was admixed with 0.2 ml of a solution prepared by

dissolving sodium chloride in a concentration of 0.3M in a 0.1M acetate buffer solution of pH 4.0 and the mixture was kept at 37 °C for 20 minutes. The mixture was further admixed with 0.1 ml of the above obtained ethyl alcohol extract solution or hot water extract solution as dissolved in a 1/15M phosphate buffer solution of pH 7.0 containing potassium dihydrogen phosphate and disodium hydrogen phosphate and the mixture was incubated at 37 °C for 20 minutes. The mixture was then further admixed with 0.2 ml of a solution prepared by dissolving 1.83 mg of a potassium salt of hyaluronic acid originating in cock's comb (a product by Sigma Co.) in 1 ml of a 1M acetate buffer solution and kept standing at 37 °C for 20 minutes. Thereafter, the mixture was further admixed with 0.1 ml of a 0.4N aqueous sodium hydroxide solution and 0.1 ml of a 0.8M aqueous sodium borate solution and boiled for 3 minutes followed by cooling and addition of 3.0 ml of a solution prepared by dissolving 10 g of 4-dimethylaminobenzaldehyde and 12.5 ml of 10N hydrochloric acid in 87.5 ml of acetic acid and 10 times diluted with acetic acid. After standing for 20 minutes at 37 °C, this solution was subjected to the spectrophotometric measurement of the absorbance at a wavelength of 585 nm.

The hyaluronidase activity inhibition HI was calculated from the equation:

25
$$HI (\%) = [(Y - X) - (Z - X)] / (Y - X) \times 100,$$

in which X is the absorbance of the control solution containing neither the hyaluronidase nor sample solution, Y is the absorbance of the solution containing hyaluronidase only and Z is the absorbance of the solution for measurement prepared by adding hyaluronidase to the sample solution. The results for the culturing runs A to H are shown in Table 1.

T a b l e 1

Cul- ture run	Auxil- iary addi- tives	Cultur- ing time, hours	HI, %		IH _{ex} , %	
			Hot water extract	Ethyl alcohol extract	Hot water extract	Ethyl alcohol extract
A	None	72	15.6	22.1	0.6	36.4
B	None	120	12.3	19.8	0	26.9
C	Wheat bran	72	8.7	23.7	5.8	47.8
D	Bagasse	72	9.4	24.6	26.8	85.2
E	Wheat bran Bagasse	72	12.6	18.6	17.4	74.3
F	Wheat bran Bagasse	120	13.4	21.2	0	38.9
G	Wheat bran Pinewood chips	72	11.4	40.6	34.8	92.4
H	Wheat bran Pinewood chips	120	18.6	86.8	5.3	64.7

5 As is clear from this table, the HI value for the ethyl
alcohol extract is definitely greater than the HI value of
the hot water extract for the same agaric fungous bodies
grown in each of the culturing runs A to H. The difference
is particularly prominent when culturing is conducted in a
10 liquid culture medium admixed with wheat bran and pinewood
chips in combination as is the case in the culturing runs G
and H.

Assay 2

Each of the ethyl alcohol extracts and hot water extracts was subjected to the assay of allergenic cell activity inhibition in the following manner by using
5 basophilic leukocytes as the allergenic cells. In conducting the assay tests, following preparatory solutions were prepared beforehand.

(1) Substrate solution, 5 mM concentration

The solution was prepared by dissolving 85.5 mg of 4-
10 nitrophenyl-N-acetyl- β -D-glucosamide (Sigma N9376) as the substrate in 50 ml of a 50mM citrate buffer solution of pH 4.5.

(2) Mixed releasing solution, pH 7.7

The solution was prepared by dissolving, in 500 ml of
15 water, 3.42 g of sodium chloride, 201 mg of potassium chloride, 98.6 mg of magnesium sulfate heptahydrate, 504 mg of glucose, 3.0 g of a buffering agent (HEPES), 111 mg of calcium chloride and 0.5 g of bovine serum albumin followed by adjustment of the pH to 7.7 and sterilizing filtration.

20 (3) Reaction stopper solution

The solution was a 100mM carbonate buffer solution of pH 10.0 containing 1.06 g/100 ml of sodium carbonate and 0.84 g/100 ml of sodium hydrogencarbonate.

(4) 4 μ g/ml DNP-BSA solution

25 The solution was prepared by 25 times dilution of a solution containing 1 mg/10 ml of bovine serum albumin (DNP-BSA, Cosmobio LG0017) in a phosphate buffer solution with the same phosphate buffer solution followed by sterilizing filtration.

30 (5) 1 mg/ml solution of mouse anti-DNP IgE antibody (Sigma D8406)

(6) 3mM ketotifen solution

The solution was prepared by dissolving 12.8 mg of ketotifen fumarate having a molecular weight of 425.5 (Sigma
35 K2628) in 10 ml of a phosphate buffer solution followed by sterilizing filtration.

The assay procedure was as described below by using a 75 cm² flask which could serve for inoculation of two or more of 24-well plates.

After a trypsin treatment of the cells in a flask to
5 facilitate releasing of the cells from the wall by keeping
the flask in a carbon dioxide incubater for 5 minutes with
addition of trypsin followed by gentle tapping of the flask,
the liquid culture medium was added to the flask followed by
a centrifugal treatment. The thus trypsin-treated cells were
10 suspended in about 5 ml of the culture medium and the cell
concentration of the suspension was adjusted to 5×10^5 cells
per ml by dilution with the culture medium followed by the
addition of the preparatory solution (5) in a 1/3333 volume
to give a final concentration of 0.3 µg/ml with shaking to
15 effect thorough suspension of the cells. A 24-well plate was
inoculated with the cell suspension in a volume of 500 µl per
well and kept standing in a carbon dioxide incubater
overnight to sensitize the cells.

The cells after the overnight standing in the incubater
20 were twice washed with a 1 ml volume of a phosphate buffer
solution and then 260 µl of the preparatory solution (2) were
added thereto in combination with 20 µl of the sample
solution or the phosphate buffer solution as a control
followed by 10 minutes incubation in the carbon dioxide
25 incubater. After further incubation for 1 hour in the carbon
dioxide incubater with addition of 20 µl of the preparatory
solution (4), the solution was recovered in an Eppendorf tube
and subjected to a centrifugal treatment. A 100 µl portion
of the supernatant was admixed with 400 µl of the preparatory
30 solution (1) and incubated at 37 °C for 30 minutes followed
by the addition of 1 ml of the preparatory solution (3) to be
subjected to the spectrophotometric measurement at a
wavelength of 405 nm.

Measurements were made for three samples (n=3) in which a 1300 µl portion of the preparatory solution (2) to be added to the cells was admixed in advance with 100 µl of the sample solution. The volume of the sample solution was decreased to 5 10 µl when the sample solution was a 70% ethyl alcohol extract solution in order to reduce the influence by the ethyl alcohol. The solution left after addition to the cells was admixed likewise with the preparatory solutions (4) and (3) for the measurements of the absorbance to give the 10 background level of the spectrophotometric measurement.

Inhibition against hexosaminidase liberation IH_{ex} , %, was calculated by using the equation:

$$IH_{ex} (\%) = [1 - (a - b)/(c - d)] \times 100,$$

in which a is the absorbance with addition of the sample to 15 the cells, b is the absorbance with addition of the sample in the absence of the cells, c is the absorbance as a control by the admixture of the cells with a phosphate buffer solution or 70% ethyl alcohol 5-times diluted with a phosphate buffer solution and d is the absorbance by the addition of the 20 control in the absence of the cells. The results of the calculation for the values of IH_{ex} in each of the culture runs A to H are shown also in Table 1.

As is understood from the IH_{ex} values tabulated in Table 1, the ethyl alcohol extract of the fungous body tissues in 25 each of the culture runs exhibits stronger allergenic cell activity inhibition than the corresponding hot water extract. In particular, the difference is prominent in the culture runs with addition of wheat bran and pinewood chips in combination to the culture medium as is the case in the 30 culturing run G.

Industrial Applicability

The above described experimental results support the conclusion that the ethyl alcohol extract from tissues of 35 bodies and/or mycelia of the agaric fungous contains

substances capable of exhibiting inhibition against hyaluronidase activity and allergenic cell activity in large amounts as compared with the hot water extract so that the extract is useful as an effective ingredient in an anti-inflammatory and antiallergic medicament. Since the ethyl alcohol extract is free from the safety problem against human body and can be prepared by a simple and inexpensive procedure, the applicability of the extract is not limited to the medicaments mentioned above but also includes the application as an additive in foods and cosmetic or toiletry compositions in general.

CLAIMS

1. A hyaluronidase activity and allergenic cell activity inhibitive substance which is an ethyl alcohol extract
5 from body tissues or mycelia tissues of a fungus *Agaricus blazei*.
2. A method for the preparation of a hyaluronidase activity and allergenic cell activity inhibitive substance which
10 comprises the steps of:
 - (a) mashing body tissues or mycelia tissues of a fungus *Agaricus blazei* to give a mash of the fungus tissues;
 - (b) adding ethyl alcohol to the mash of the fungus tissues to give an ethyl alcohol extract solution; and
 - 15 (c) removing at least a part of the ethyl alcohol from the ethyl alcohol extract solution.
3. The method for the preparation of a hyaluronidase activity and allergenic cell activity inhibitive substance
20 according to claim 2 wherein the fungous bodies or mycelia of the fungus are obtained by culturing the fungus in an artificial culture medium.
4. The method for the preparation of a hyaluronidase
25 activity and allergenic cell activity inhibitive substance according to claim 3 wherein the artificial culture medium contains wheat bran and pinewood chips in combination each in an amount in the range from 0.2 to 3 g per liter.
- 30 5. A method for therapeutic anti-inflammatory treatment of a patient which comprises administrating the patient with the hyaluronidase activity and allergenic cell activity inhibitive substance as defined in Claim 1.
- 35 6. A method for therapeutic antiallergic treatment of a patient which comprises administrating the patient with the

hyaluronidase activity and allergenic cell activity
inhibitive substance as defined in Claim 1.

INTERNATIONAL SEARCH REPORT

Inte onal Application No
PL, JP 01/02236

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K35/84 A61P37/08 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, FSTA, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	WO 00 65029 A (TSUKUBA BIOSYSTEM LTD ;INTABON KEO (JP); MAEKAWA TAKAAKI (JP)) 2 November 2000 (2000-11-02) page 3, line 30 -page 7, line 4 ---	1-6
X	DATABASE WPI Section Ch, Week 199839 Derwent Publications Ltd., London, GB; Class B04, AN 1998-456765 XP002180151 & WO 98 35546 A (IMB KK), 20 August 1998 (1998-08-20) abstract --- -/--	1-6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

15 October 2001

Date of mailing of the international search report

26/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Rempp, G

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 01/02236

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>PATENT ABSTRACTS OF JAPAN vol. 1999, no. 10, 31 August 1999 (1999-08-31) & JP 11 130690 A (HIGAKI MIYATO;YOSHIMOTO HIROAKI), 18 May 1999 (1999-05-18) abstract</p> <p>---</p>	1
A	<p>PATENT ABSTRACTS OF JAPAN vol. 018, no. 427 (C-1235), 10 August 1994 (1994-08-10) & JP 06 128164 A (HITOSHI ITO;OTHERS: 01), 10 May 1994 (1994-05-10) abstract</p> <p>---</p>	
A	<p>PATENT ABSTRACTS OF JAPAN vol. 1999, no. 08, 30 June 1999 (1999-06-30) & JP 11 080016 A (NOEVIR CO LTD), 23 March 1999 (1999-03-23) abstract</p> <p>-----</p>	

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 5,6 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 5,6

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 01/02236

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0065029	A	02-11-2000	WO 0065029 A1	02-11-2000
WO 9835546	A	20-08-1998	AU 5879298 A WO 9835546 A1	08-09-1998 20-08-1998
JP 11130690	A	18-05-1999	NONE	
JP 06128164	A	10-05-1994	NONE	
JP 11080016	A	23-03-1999	NONE	